<bill session="116" type="s" number="3945" updated="2020-12-28T14:41:25Z">
  <state datetime="2020-06-11">REFERRED</state>
  <status>
    <introduced datetime="2020-06-11"/>
  </status>
  <introduced datetime="2020-06-11"/>
  <titles>
    <title type="display">Bring Entrepreneurial Advancements To Consumers Here In North America Act</title>
    <title type="short" as="introduced">Bring Entrepreneurial Advancements To Consumers Here In North America Act</title>
    <title type="official" as="introduced">A bill to amend the Internal Revenue Code of 1986 to provide incentives for relocating manufacturing of pharmaceuticals and medical supplies and devices to the United States.</title>
  </titles>
  <sponsor bioguide_id="L000594"/>
  <cosponsors>
    <cosponsor bioguide_id="C001098" joined="2020-06-11"/>
    <cosponsor bioguide_id="E000295" joined="2020-06-11"/>
  </cosponsors>
  <actions>
    <action datetime="2020-06-11">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2020-06-11" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSFI" name="Senate Finance" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="116" relation="unknown" number="6690"/>
  </relatedbills>
  <subjects>
    <term name="Taxation"/>
    <term name="Accounting and auditing"/>
    <term name="Business expenses"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Income tax deductions"/>
    <term name="Income tax exclusion"/>
    <term name="Industrial facilities"/>
    <term name="Manufacturing"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2020-06-11T04:00:00Z" status="Introduced in Senate">Bring Entrepreneurial Advancements To Consumers Here In North America Act

This bill allows accelerated depreciation of nonresidential real property acquired to relocate facilities for the manufacture of pharmaceuticals and medical devices or supplies in the United States. It also allows an exclusion from gross income of gain from the sale or exchange of relocation property that was used to manufacture medical products in a foreign country.</summary>
  <committee-reports/>
</bill>
